This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Masarykova Univerzita. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Karla Plevova: Innovator in Chronic Lymphocytic Leukemia Research
Introduction
Karla Plevova is a distinguished inventor based in Hostalkova u Vsetina, Czech Republic. She has made significant contributions to the field of medical research, particularly in the diagnosis and prognosis of B-cell chronic lymphocytic leukemia (CLL). Her innovative work has the potential to improve patient outcomes through advanced diagnostic methods.
Latest Patents
Karla Plevova holds a patent for a method of determination of diagnosis and prognosis in patients with B-cell chronic lymphocytic leukemia. This patent, which includes 1 patent, outlines a method that utilizes biological samples collected from patients to assess the status of the Wnt/PCP signaling pathway. The invention identifies the relationship between CLL and the molecular signaling pathway, which is significantly up-regulated in B-lymphocytes of affected patients. The method can determine the expression of components of the signaling pathway or the migration of CLL cells in response to chemokine gradients.
Career Highlights
Karla Plevova is affiliated with Masarykova Univerzita, where she conducts her research and develops her innovative methods. Her work has garnered attention in the scientific community, contributing to advancements in understanding and treating chronic lymphocytic leukemia.
Collaborations
Karla has collaborated with notable colleagues, including Vitezslav Bryja and Pavel Krejci. These partnerships have enhanced her research efforts and expanded the impact of her work in the field of oncology.
Conclusion
Karla Plevova's contributions to the diagnosis and prognosis of B-cell chronic lymphocytic leukemia exemplify the importance of innovation in medical research. Her patented methods and collaborative efforts continue to pave the way for advancements in cancer treatment and patient care.